Digital pharmacy startup ScriptDash rebrands as Alto, raises $23M Series B led by Greenoaks Capital for nationwide expansion
Sarah Buhr / TechCrunch :
Context & Ripple Effects
ScriptDash is rebranding as Alto and taking a $23M Series B from Greenoaks Capital to push its same-day delivery and medication-management model beyond its home market — the second act in a delivery-pharmacy arc that began when PillPack locked in $50M to take on Walgreens two years earlier.
The bet pays off down the line in the related coverage: Greenoaks returns for Alto's $50M Series C, and by early 2020 the company has raised ~$250M led by SoftBank at a valuation over $1B, confirming this round as the inflection point where a regional courier became a national platform.
First-order effects
- Greenoaks Capital now owns an early position in a company that will become one of the most heavily capitalized digital pharmacies, while Alto gets the war chest to fund a nationwide rollout of same-day prescription delivery.
Second-order effects
- Incumbents CVS and Walgreens are forced to treat delivery-first startups as a real channel threat rather than a niche service — the framing that later groups Alto, Capsule, and Medly together as disruptors with $650M+ raised since January 2020.
Third-order effects
- Capital keeps flowing into every layer of the pharmacy stack — delivery players like ScriptDrop raising $15M, and benefit-management startup Capital Rx eventually reaching $607M+ — pointing toward pharmacy distribution being rebuilt around venture-funded software platforms rather than storefront networks.
The trend: Pharmacy retail is shifting from store-based pickup to venture-subsidized home delivery, with each funding round widening the gap between platform pharmacies and incumbent chains.